A recent study found that the carbon footprint of a disposable cystoscope was “significantly lower” than the reusable alterative. An opposing letter to the editor, however, expresses two “serious methodical concerns” with the study.
Bacillus Calmette-Guerin will always be the bladder cancer treatment standard that new treatments will be challenged to meet. What’s needed now, experts say, is a set of comparative trials demonstrating an alternative treatment.
The April 1 notice from Karl Storz lists 28 products, including flexible cystoscopes and ureteroscopes. Customers without access to “an appropriate sterilization method” should discontinue their use and return the scopes.
Over the last four years, the FDA received more than 450 medical device reports describing post-procedure patient infections or other potential contamination issues involving reprocessed urological endoscopes. The agency says it’s investigating potential causes and contributing factors.
These findings are significant because, until now, population-level data assessing the incidence of kidney stones has been limited in the U.S. A persistent increase in kidney stone incidence may create a significant need for more healthcare resources.